ScholarLens Back to search
2012•Transplantation and Cellular TherapyOpen access

Busulfan, Cyclophosphamide, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)?

Galena Salem, A. S. Ruppert, Yvonne Adeduni Efebera, Patrick Elder, Anissa K. Bingman, Sam L. Penza, Leslie Ann Andritsos, Steven Michael Devine

Open full text 0 citations

Abstract

Busulfan (Bu) based conditioning regimens were developed for use in ASCT for HL with the goal to reduce the risk of relapse without increasing toxicity in comparison to more conventional regimens such as BEAM. At Ohio State, Bu was combined with cyclophosphamide (CY) and VP-16 (BUCYVP) and became the standard conditioning regimen here for 15 years. In 2005, we switched to the BEAM regimen.

Open-access reader

About this research paper

What this paper is about

Busulfan (Bu) based conditioning regimens were developed for use in ASCT for HL with the goal to reduce the risk of relapse without increasing toxicity in comparison to more conventional regimens such as BEAM. At Ohio State, Bu was combined with cyclophosphamide (CY) and VP-16 (BUCYVP) and became the standard conditioning regimen here for 15 years. In 2005, we switched to the BEAM regimen.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Busulfan (Bu) based conditioning regimens were developed for use in ASCT for HL with the goal to reduce the risk of relapse without increasing toxicity in comparison to more conventional regimens such as BEAM. At Ohio State, Bu was combined with cyclophosphamide (CY) and VP-16 (BUCYVP) and became the standard conditioning regimen here for 15 years. In 2005, we switched to the BEAM regimen.

Key concepts: Medicine, Etoposide, Carmustine, Busulfan, Cyclophosphamide, Autologous stem-cell transplantation, Regimen, Cytarabine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Busulfan, Cyclophosphamide, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)? — Research Paper | ScholarLens